Information Provided By:
Fly News Breaks for May 16, 2017
BDSI
May 16, 2017 | 16:35 EDT
As previously reported, Cantor upgraded BioDelivery Sciences to Overweight from Neutral and raised its price target to $4 from $3. Analyst Chiara Russo believes the company is at an inflection point with commercial execution consisting of growing Belbuca Rx combined with a strong shift into payers. The analyst said BioDelivery has increased Rx per month and the base and expects topline growth ton continue through 2017 with potential upside from additional partnering opportunities and Medicare expansion.
News For BDSI From the Last 2 Days
There are no results for your query BDSI